Mmc clinical trials_apr05
Memorial Medical Center1700 Coffee RoadModesto, CA 95355(209) 572-7237
Clinical Trials April 2005
A Phase III Trial Evaluating the Role of Ovarian Function Suppression
and the Role of Exemestane as Adjuvant Therapies for PremenopausalWomen with Endocrine Responsive Breast Cancer.
A Randomized Phase III Trial of Exemestane vs. Anastrozole With or
Without Celecoxib in Postmenopausal Women with Receptor PositivePrimary Breast Cancer (** temporarily closed to accrual).
Quality of Life Companion Study for MA.27 (NEW)
A Clinical Trial Comparing Anastrozole with Tamoxifen in
Postmenopausal Patients with Ductal Carcinoma In-Situ (DCIS)Undergoing Lumpectomy with Radiation Therapy.
A Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens
in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophospha-mide Followed by DD Paclitaxel (DD AC P); DD AC Followed byDD Paclitaxel Plus Gemcitabine (DD AC PG).
Phase III Trial of Observation +/- Tamoxifen vs. RT +/- Tamoxifen for
Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast.
Phase III Trial of Continuous Schedule AC + G vs. Every 2 WeekSchedule AC, Schedule AC, Followed by Paclitaxel Given Either Every 2Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy inNode-Positive or High-Risk Node Negative Breast Cancer.
Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed byWeekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment forWomen with HER-2 Overexpressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer.
A Randomized Phase III Trial of Irinotecan (CPT-11) and/or
Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or Without Cetuximab(C225) after Curative Resection for Patients with Stage III Colon Cancer.
Intergroup Randomized Phase III Study of Postoperative Irinotecan,
5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil andLeucovorin vs. 5-Fluorouracil and Leucovorin for Patients with Stage IIor III Rectal Cancer Receiving Either Preoperative Radiation and5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil(** temporarily closed to accrual).
A Randomized Phase III Study of Gemcitabine in Combination withRadiation Radiation Therapy versus Gemcitabine Alone in Patients withLocalized, Unresectable Pancreatic Cancer.
A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, andRadiotherapy vs. 5-Fluorouracil, Cisplatin and Radiotherapy in Carcinomaof the Anal Canal.
Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of80101
Gastric or Gastroesophageal Adenocarcinoma.
A Randomized Phase III Trial of Gemcitabine plus Bevacizumab vs.80303
Gemcitabine plus Placebo in Patients with Advanced Pancreatic Cancer.
Phase III Randomized Trial Comparing Intermittent vs. ContinuousAndrogen Suppression for Patients with Prostate-Specific-AntigenProgression in the Clinical Absence of Distant Metastases FollowingRadiotherapy for Prostate Cancer.
A Randomized Phase III Trial of ABVD vs. Stanford V +/- Radiation Therapyin Locally Extensive and Advanced Stage Hodgkin’s Disease.
Randomized Phase III Trial Comparing Two Different Rituximab DosingRegimens for Patients with Low Tumor Burden Indolent non-Hodgkin’sLymphoma.
A Phase II Trial of STI-571/Imatinib (Gleevec) in NeuroendocrineCarcinoma of the Skin (Merkel Cell Carcinoma).
Study of Epoetin Alpha vs. Epoetin Alpha with Dexamethasone inHormone Refractory Prostate Cancer Patients: Impact on Anemia,Fatigue, Functional Status and Quality of Life.
A Phase III Prospective Randomized, Double-Blind, Placebo-ControlledTrial of the Epidermal Growth Factor Receptor Antagonist, ZD 1839(IRESSA) in Completely Resected Primary Stage IB, II, IIIA Non-SmallCell Lung Cancer.
A Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy,With or Without Thalidomide, in Patients with Stage III Non-Small CellLung Cancer.
Phase III Chemoprevention Trial of Selenium Supplementation in Personswith Resected Stage I Non-Small Cell Lung Cancer.
For any additional information regarding the above Clinical Trials,
contact Denise Galbawy RN, Cancer Research Coordinator, at 572-7116.
The HNE Performance Formulary is our innovative, 2-Tier pharmacy benefit. Tier 1 includes all generic drugs and has the lowest copay. Tier 2 includes specific brand name drugs carefully selected based on clinical efficacy and cost efficiency. When we designed this formulary, we made sure that at least one medication is available to treat each disease state. If a medication is not listed in the
Available online on www.ijcpr.com (ISSN: 0976 822X) International Journal of Current Pharmaceutical Review and Research Volume 1, Issue 3, November 2010 - January 2011 Research Article Formulation, Development and Evaluation of floating tablet of Metformin Hydrochloride using optimization of gas generating agent Department of Pharmaceutical Sciences, Jaipur National Unive